The Myasthenia Gravis Foundation of America (MGFA) is the only national volunteer health agency in the United States dedicated solely to the fight against myasthenia gravis. MGFA serves patients, their families and caregivers through a network of chapters, support groups and programs. Each chapter shares the vision of a world without MG.
Myasthenia gravis (pronounced My-as-theen-ee-a Grav-us) comes from the Greek and Latin words meaning "grave muscular weakness." The most common form of MG is a chronic autoimmune neuromuscular disorder that is characterized by fluctuating weakness of the voluntary muscle groups. To learn more click here.
The Myasthenia Gravis Foundation of America is proud to announce its 2015 awards for outstanding service and contributions to the MG Community. To learn more about this year's honorees click here.
The MGFA is thrilled to announce a new awareness and fundraising initiative…Team ENDurance MG! This exciting program will empower all participants to raise funds for the MGFA and spread awareness about myasthenia gravis while training & participating in a “bucket list” activity such as a half or full marathon, triathlon or even an obstacle course race in mud! Learn more here!
The MGFA reached out to Dr. Jon Lindstrom, whose work, along with co-investigators, has focused on the possibility of a vaccine for MG as reported recently in the Journal of Immunology. Read more here.
We are now able to accept vehicle donations. For more information, click here.
Transformative Research Awards for Myasthenia Gravis and Related Neuromuscular Junction Disorders
Alexion Pharmaceuticals is conducting a clinical trial to determine if eculizumab is effective for the treatment of patients with refractory generalized Myasthenia Gravis (gMG). The enrollment for this study is complete. For information on MG and update on the study click here.
The MG Walk, has named "MG Walk Heroes" across each of the cities in which the Walks are taking place across the nation. Click here to read these heroes' stories.
The Network for Excellence in Neuroscience Clinical Trials (NeuroNEXT) is currently looking for people with myasthenia gravis (MG) to be part of a research study. Read more here
Rituximab Study FAQs
Additional Rituximab Study Information
The American Society of Health System Pharmacists reported a shortage of Imuran. For more details, please click here.
The 2016 National Conference will be in Raleigh, NC May1st - May 3rd. We hope to see you there! We will post additional details shortly.
To view videos from the 2015 National Conference click here.
There is no known cure for MG, but there are effective treatments that allow many-but not all-people with MG to lead full lives. Although the treatments will not cure MG, patients may have significant improvement in their muscle strength.